Li Yan
Chief Tech/Sci/R&D Officer presso Brii Biosciences Ltd.
Profilo
Li Yan is currently the Chief Medical Officer at Brii Biosciences Ltd.
He previously worked as the Vice President at GSK Plc.
Prior to that, he was the Chief Medical Officer at Brii Biosciences Ltd.
(China) from 2018 to 2023.
Dr. Yan received his doctorate degree from the University of Kansas in 1996 and his undergraduate degree from Peking University Health Science Center in 1991.
Posizioni attive di Li Yan
| Società | Posizione | Inizio |
|---|---|---|
Brii Biosciences Ltd.
 Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC. | Chief Tech/Sci/R&D Officer | - |
Precedenti posizioni note di Li Yan
| Società | Posizione | Fine |
|---|---|---|
| BRII BIOSCIENCES LIMITED | Chief Tech/Sci/R&D Officer | 05/07/2023 |
| GSK PLC | Corporate Officer/Principal | - |
Formazione di Li Yan
| University of Kansas | Doctorate Degree |
| Peking University Health Science Center | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| GSK PLC | Health Technology |
| BRII BIOSCIENCES LIMITED | Commercial Services |
| Aziende private | 1 |
|---|---|
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC. | Health Technology |
- Borsa valori
- Insiders
- Li Yan
